BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Rating of “Buy” from Brokerages

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have earned a consensus rating of “Buy” from the seventeen analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, twelve have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $404.14.

ONC has been the subject of a number of analyst reports. TD Cowen increased their price objective on BeOne Medicines from $424.00 to $454.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. lifted their target price on shares of BeOne Medicines from $425.00 to $445.00 and gave the stock an “overweight” rating in a research note on Thursday, October 1st. Royal Bank Of Canada lowered their price target on shares of BeOne Medicines from $451.00 to $450.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Nomura raised shares of BeOne Medicines to a “strong-buy” rating in a research report on Monday, July 27th. Finally, Barclays raised their price target on shares of BeOne Medicines from $407.00 to $415.00 and gave the stock an “overweight” rating in a report on Thursday, September 10th.

Insider Activity at BeOne Medicines

In related news, CEO John Oyler sold 54,892 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $358.15, for a total value of $19,659,569.80. Following the sale, the chief executive officer directly owned 240,743 shares of the company’s stock, valued at $86,222,105.45. This trade represents a 18.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Xiaodong Wang sold 31,028 shares of the business’s stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $364.79, for a total value of $11,318,704.12. Following the transaction, the insider owned 31,028 shares in the company, valued at approximately $11,318,704.12. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 632,975 shares of company stock valued at $211,070,198 in the last quarter. 6.19% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BeOne Medicines

Large investors have recently made changes to their positions in the business. Renaissance Technologies LLC purchased a new stake in shares of BeOne Medicines in the 1st quarter worth about $19,438,000. BNP Paribas Financial Markets boosted its stake in shares of BeOne Medicines by 100.6% during the 4th quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock valued at $58,924,000 after purchasing an additional 97,244 shares in the last quarter. Rokos Capital Management LLP purchased a new position in shares of BeOne Medicines during the first quarter valued at about $4,256,000. SEB Asset Management AB purchased a new position in shares of BeOne Medicines during the first quarter valued at about $16,653,000. Finally, Generali Investments Management Co LLC bought a new position in BeOne Medicines in the second quarter worth about $2,280,000. 48.55% of the stock is currently owned by institutional investors.

BeOne Medicines Stock Up 1.0%

ONC opened at $361.65 on Thursday. BeOne Medicines has a 12 month low of $253.95 and a 12 month high of $385.22. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. The business’s 50-day moving average price is $354.67 and its 200-day moving average price is $316.94. The company has a market cap of $39.71 billion, a P/E ratio of 63.67 and a beta of 0.61.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.65. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%.The company had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.66 billion. On average, equities analysts expect that BeOne Medicines will post 8.81 EPS for the current year.

About BeOne Medicines

BeOne Medicines Ltd. (NASDAQ: ONC) is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for people with cancer. The company operates across the research and development, clinical testing, regulatory and commercial stages of the biopharmaceutical industry, with an emphasis on treatments for blood cancers and solid tumors.

Its marketed portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used to treat several B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy targeting the PD-1 pathway for certain cancers.